Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

KERX $5.96 0.5200 +9.56%
NLNK $17.62 1.4050 +8.67%
LOXO $24.98 1.9300 +8.37%
MNKD $1.45 0.1000 +7.41%
CORT $5.05 0.2800 +5.87%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CBMG $15.54 -1.7300 -10.02%
PVCT $0.44 -0.0489 -9.98%
BDSI $3.11 -0.2700 -7.99%
VRML $1.30 -0.0900 -6.47%
CERU $3.10 -0.1800 -5.49%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

Agendia’s MammaPrint® First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients

(Agendia) Apr 18, 2016 - Agendia, Inc., together with the European Organisation for Research and Treatment of Cancer (EORTC) and Breast International Group (BIG), announced results from the initial analysis of the primary objective of the Microarray In Node-negative (and 1 to 3 positive lymph node) Disease may Avoid ChemoTherapy (MINDACT) study at the American Association for Cancer Research Annual Meeting 2016 in New Orleans, LA.
read corporate press release 

Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting

(Merck) Apr 19, 2016 - Merck, known as MSD outside the United States and Canada, is proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an important initiative to compare several new diagnostic tests for the immune biomarker PD-L1 in non-small cell lung cancer (NSCLC).
read corporate press release 

Delays in Radiation Therapy Increase Chance of Breast Tumor Development in Women Treated for Ductal Carcinoma in Situ

(AACR) Apr 18, 2016 - Women who underwent treatment for ductal carcinoma in situ (DCIS), a noninvasive breast abnormality, were at higher risk of developing malignant breast tumors if they did not receive timely radiation therapy as part of their treatment, according to a study presented here at the AACR Annual Meeting 2016, April 16-20.
read press release 

Immunotherapy Drug Shrinks Tumors in Half of Patients with Rare, Virus-Linked Skin Cancer

(Johns Hopkins Medicine) Apr 19, 2016 - In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy.
read press release 

First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

(StreetInsider) Apr 19, 2016 - Bristol-Myers Squibb Company announced today the first presentation of data from CheckMate -141, a Phase 3 open-label, randomized trial, evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum therapy compared to investigator’s choice of therapy (methotrexate, docetaxel, or cetuximab).
read article 

Bristol-Myers's Opdivo Extends Survival in Head, Neck Cancer

(Bloomberg) Apr 19, 2016 - Drug lengthened median survival to 7.5 months from 5.1 months; one-year survival was 36% for Opdivo, 17% for current therapy.
read article 

Pfizer Announces Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE® (Palbociclib)

(Pfizer) Apr 19, 2016 - Phase 3 Trial provides confirmatory evidence for IBRANCE in the first-line setting and will support global regulatory submissions.
read corporate press release 

The List Of Cancers Being Taken Down By Immunotherapy Keeps Growing

(Washington Post/To Your Health) Apr 19, 2016 - New immunotherapy drugs are showing significant and extended effectiveness against a broadening range of cancers, including rare and intractable tumors often caused by viruses. Researchers say these advances suggest the treatment approach is poised to become a critical part of the nation’s anti-cancer strategy.
read article (free registration required) 

Roche Sees Its First Cancer Immunotherapy Winning U.S. Nod Soon

(Bloomberg) Apr 19, 2016 - Roche Holding AG said its most advanced experimental drug to harness the immune system in the fight against cancer may win U.S. regulatory approval this year, becoming the first such treatment to help the roughly 430,000 people diagnosed annually with bladder cancer.
read article 

Heron Therapeutics Provides Update on FDA Review of SUSTOL® NDA

(Yahoo! Finance) Apr 18, 2016 - Heron Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has provided the Company with an update on its review of the New Drug Application (NDA) for SUSTOL® (granisetron) Injection, extended release. The FDA has indicated that there are no substantive deficiencies in the NDA and has begun labeling discussions with the Company.
read article 

Delaying Radiation Therapy For Women With Very Early Breast Cancer Ups Recurrence

(Washington University School of Medicine) Apr 18, 2016 - Delaying radiation therapy too long after surgery significantly increases the risk of recurrent tumors in women treated for very early, or what is referred to as “stage 0,” breast cancer, according to new research at Washington University School of Medicine in St. Louis.
read press release 

AstraZeneca Mulls £7Bn Move For Prostate Cancer Drug Company Medivation

(The Telegraph [UK]) Apr 17, 2016 - AstraZeneca is mulling a £7bn offer for the US drug company Medivation after it rejected a bid from a French rival.
read article 

New RAF-targeted Therapeutic Shows Early Promise Against Tumors With BRAF and RAS Mutations

(AACR) Apr 17, 2016 - The new investigational anticancer therapeutic BGB-283, which targets the RAF family of proteins, was safe, tolerable, and showed signs of clinical activity in patients who had a range of types of cancer with mutations in BRAF, KRAS, and NRAS, according to results from a phase I clinical trial presented here at the AACR Annual Meeting 2016, April 16-20.
read press release 

'Innovation Center' Tries to Reinvent Medicare

(ABC News/Associated Press) Apr 18, 2016 - They work for the government and even their closest relatives have no idea what they do. It's not because they're spies or nuclear scientists, but because their jobs are so arcane: trying to reinvent Medicare to improve it, and maybe save taxpayers money.
read article 

US Widens Use Of Boehringer's Lung Cancer Drug Gilotrif

(PharmaTimes [UK]) Apr 17, 2016 - US health officials have expanded the approved indications for Boehringer Ingelheim’s Gilotrif, clearing its use in patients with squamous cell carcinoma of the lung.
read article 

American Association for Cancer Research Inaugurates New Leadership at 2016 Annual Meeting

(AACR) Apr 18, 2016 - The American Association for Cancer Research (AACR) welcomes Nancy E. Davidson, MD, director of the University of Pittsburgh Cancer Institute, as President of the organization for 2016-2017. She was inaugurated during the Annual Business Meeting, held here during the AACR Annual Meeting 2016.
read press release 

Sosei Subsidiary Heptares and Kymab Enter Strategic Collaboration to Discover, Development and Commercialise Novel Antibody Therapeutics

(Sosei) Apr 18, 2016 - Sosei Group Corporation today announces Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei, and Kymab Limited, a leading human monoclonal antibody biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel antibody therapeutics targeting a number of G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology.
read corporate press release 

Predicine, CloudHealth Form Strategic Partnership on Liquid Biopsy Cancer Tests

(SYS-CON Media) Apr 18, 2016 - Predicine, Inc. and Shanghai-based firm, CloudHealth Genomics, Ltd. today announced an agreement to jointly promote Predicine's next-generation sequencing (NGS)-based liquid biopsy diagnostic tests in the China oncology market.
read article 

PhRMA Releases New Patient Stories as Part of "From Hope to Cures" Advertising Campaign

(Morningstar) Apr 18, 2016 - New ads feature cancer survivors.
read article 

Care for UK Cancer Patients Still Expensive Almost A Decade After Treatment

(City University London [UK]) Apr 15, 2016 - Cancer survivors diagnosed almost a decade ago still cost the NHS in England five times more than someone without the disease, according to new research published this week in the British Journal of Cancer.
read article 

Mistakes By Both Sides Led To Vidaza NICE Rejection, Says Celgene

(Pharmaforum [UK]) Apr 15, 2016 - Celgene has said it will fight to ensure patients get access to its blood cancer drug Vidaza (azacitadine) following its rejection by NICE, saying that mistakes by both organisations led to a huge difference in cost-effectiveness estimates.
read article 

Tennessee Oncology Selected for Oncology Care Model

(Tennessee Oncology) Apr 14, 2016 - Tennessee Oncology has been selected to participate in the Centers for Medicare and Medicaid Services Oncology Care Model for a five-year period, beginning July 1.
read press release 

Radiotherapy Demand Will Rise Sharply Over Next Decade

(OnMedica [UK]) Apr 18, 2016 - Demand for radiotherapy across all European countries is set to rise substantially over the next decade, according to a study* published today in the journal Radiotherapy and Oncology.
read article 

Cancer MoonShot 2020 Forms Radiation and Immuno-Oncology Working Group to Accelerate Efforts to Win the War on Cancer

(Cancer MoonShot 2020) Apr 18, 2016 - 15 top medical oncologists, radiation oncologists and scientists collaborating from all parts of the country including Mass General, Tufts, Emory, Sanford Health, and Cedars Sinai to work on combinations of low dose radiation with cancer-directed immunotherapy.
read press release 

Anthony Fauci Is Waging War Against Zika, and Preparing for Other Epidemics to Come

( Apr 18, 2016 - The director of the National Institute of Allergy and Infectious Diseases talks about developing a Zika vaccine.
read article